Related Experiment Video

Updated: Jul 13, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Statins and C-reactive protein levels

Jordan Asher1, Mark Houston

  • 1Saint Thomas Health Services, Saint Thomas Hospital, Nashville, TN, USA.

Journal of Clinical Hypertension (Greenwich, Conn.)
|August 4, 2007
PubMed

Insights

Lowering low-density lipoprotein cholesterol (LDL-C) with statins is crucial for cardiovascular disease (CVD) risk reduction. Statins also reduce C-reactive protein (CRP), an inflammation marker, potentially offering additional cardiovascular benefits.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) risk is significantly influenced by low-density lipoprotein cholesterol (LDL-C) levels.
  • Statins are primary therapies for lowering LDL-C and reducing CVD incidence.
  • Emerging evidence suggests mechanisms beyond LDL-C reduction may contribute to statin's cardiovascular benefits.

Purpose of the Study:

  • To review the role of LDL-C lowering in CVD risk reduction.
  • To examine the impact of statins on C-reactive protein (CRP) levels.
  • To explore potential cardiovascular benefits associated with CRP reduction independent of LDL-C lowering.

Main Methods:

  • Review of extensive clinical trial data on statin efficacy.
  • Analysis of studies investigating statin effects on both LDL-C and CRP levels.
  • Evaluation of existing outcome data on CRP reduction and cardiovascular events.

Main Results:

  • Statins effectively lower LDL-C, with varying degrees of reduction depending on the specific statin.
  • Intensive LDL-C lowering demonstrates greater reduction in cardiovascular events compared to moderate lowering.
  • Statins can reduce C-reactive protein (CRP) levels by up to 60%, independent of LDL-C reduction.

Conclusions:

  • LDL-C reduction remains a cornerstone of CVD risk management with statins.
  • Statins' ability to lower CRP suggests a potential secondary mechanism for cardiovascular event reduction.
  • Further outcome data are needed to fully elucidate the cardiovascular benefits of CRP reduction.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...